2005 Fiscal Year Final Research Report Summary
Development for new cancer vaccine against heterogenicity and HLA-loss of tumor
| Project/Area Number |
16591297
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
TSUNODA Takuya The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Associate Professor, 医科学研究所, 特任助教授 (30275359)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAHARA Hideaki The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Professor, 医科学研究所, 教授 (70322071)
TAKAYAMA Takuya The University of Tokyo, Institute of Medical Science, Advanced Clinical Research Center, Department of Surgery and Bioengineering, Associate Professor, 医科学研究所, 講師 (10332579)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Keywords | Epitope peptide / Tumor heterogenicity / HLA Loss / CTL / Cancer vaccine |
|---|
| Research Abstract |
Recently, cancer vaccine using epitope peptides was performed all over the world. Epitope peptides induced the strong cytotoxic T lymphocytes (CTL) in cancer patients, therefore clinical trials of cancer vaccine were performed. However, the outcome of clinical trial has not so excellent. One of the reasons was due to the heterogenicity and HLA-loss of the tumor. To overcome these problems, we focused on the tumor angiogenesis and examined the immunogenicity for tumor-angiogenesis related targets.
In this study, we have determined the immunogenicity from these targets. We have determined epitope peptides restricted to HLA-A^*2402 which was the most common in Japanese. These findings may suggest that tumor-angiogenesis related targets are excellent targets to improve the clinical efficacy of cancer vaccine.
|
